

October 2004

**Congress Chairs**

**Mario Dicato, MD**  
Luxembourg Medical Center  
Luxembourg, Luxembourg

**Eric Van Cutsem, MD,  
PhD**  
University Hospital  
Gasthuisberg  
Leuven, Belgium

## CLINICAL SYMPOSIA REPORT

### Advances in Gastrointestinal Cancer: A Report From the World GI Congress, June 16–19, 2004, Barcelona, Spain

Supported by unrestricted  
educational grants from  
Sanofi-Synthelabo, Merck KGaA,  
and SupraGen/EuroGen

 **Imedex**<sup>®</sup>  
education is the best medicine


 **MILLENNIUM  
MEDICAL**  
PUBLISHING, INC.

 **H&O**

#### Section IV: CRC: Screening and Genetic Profiling

##### *CRC Screening Methods*

Two studies of novel experimental CRC screening methods were presented. The first study assessed the efficacy of an immune fecal occult-blood test (FOBT) for the screening of CRC in an asymptomatic moderate-risk population.<sup>110</sup> These findings suggested that immune FOBT is an effective method for the screening of CRC or adenomatous polyps, allowing early detection of the disease. The second trial showed that fecal levels of tumor pyruvate kinase type M2 (M2-PK), an isoenzyme of pyruvate kinase, were significantly higher in 207 patients with CRC than in samples of 107 patients with adenoma or 100 healthy controls ( $P < .001$ ; Figure 3).<sup>111</sup> Based on these findings, it appears that tumor M2-PK has potential as a screening tool for the early detection of CRC.



**Figure 3.** Levels of tumor M2-PK in stool

CC=colon cancer; RC=rectal cancer; CRC=colorectal cancer; M2-PK=pyruvate kinase type M2.